Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for DSSTox_CID_3557

    Client Email Product

    DSSTox_CID_3557

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    17
    US DMFs Filed

    US DMFs Filed

    15
    CEP/COS Certifications

    CEP/COS Certifications

    6
    JDMFs Filed

    JDMFs Filed

    1
    Other Certificates

    Other Certificates

    1
    Other Suppliers

    Other Suppliers

    3
    API REF. PRICE (USD / KG)

    0

    API Market Place

    4
    INTERMEDIATES
    2
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    28
    Europe

    Europe

    92
    Canada

    Canada

    4
    Australia

    Australia

    6
    South Africa

    South Africa

    3
    Uploaded Dossiers

    Uploaded Dossiers

    4
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    56.00

    Annual Reports

    1,025.00

    FDF Market Place

    6
    EXCIPIENTS
    301
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    26
    REF STANDARD

    EDQM

    1

    USP

    2

    JP

    0

    Other Listed Suppliers

    4
    SERVICES
    1
    left grey arrow
    right gray arrow
    • CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • SOLUTION;ORAL - 40MG/ML
    Full View ScreenFull Screen View
    Eiger Begins Enrollment in LIMT-2 Phase 3 Study of Peginterferon Lambda
    Eiger Begins Enrollment in LIMT-2 Phase 3 Study of Peginterferon Lambda

    https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-first-patient-enrolled-in-limt-2-a-phase-3-study-of-peginterferon-lambda-in-patients-with-chronic-hepatitis-delta-virus-hdv-infection-301449320.html

    PRNEWSWIRE
    21 Dec 2021
    Share Share
    Triple drug combination shows promise in Covid-19 treatment
    Triple drug combination shows promise in Covid-19 treatment

    https://www.clinicaltrialsarena.com/news/triple-drug-combo-covid-19/

    CLINICALTRIALSARENA
    11 May 2020
    Share Share
    Bausch Health initiates VIRAZOLE trial in Covid-19 patients
    Bausch Health initiates VIRAZOLE trial in Covid-19 patients

    https://www.clinicaltrialsarena.com/news/bausch-health-initiates-virazole-trial/

    CLINICALTRIALSARENA
    15 Apr 2020
    Share Share
    Bausch Health begins clinical study in Canada evaluating Virazole in combo
    Bausch Health begins clinical study in Canada evaluating Virazole in combo

    http://www.pharmabiz.com/NewsDetails.aspx?aid=122429&sid=2

    PHARMABIZ
    13 Apr 2020
    Share Share
    Can old drugs take down a new coronavirus?
    Can old drugs take down a new coronavirus?

    https://cen.acs.org/sections/coronavirus/biological-chemistry/infectious-disease/coronavirus-drug-repurposing.html

    Lisa M. Jarvis C&EN
    13 Mar 2020
    Share Share
    Biogen Idec's Plegridy (Peginterferon beta-1a) Receives Supplemental Approval In US
    Biogen Idec's Plegridy (Peginterferon beta-1a) Receives Supplemental Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125499

    12 Jul 2019
    Share Share
    AbbVie reports 99% cure rate for pan-genotypic Hep C therapy
    AbbVie reports 99% cure rate for pan-genotypic Hep C therapy

    http://www.pharmatimes.com/news/abbvie_reports_99_cure_rate_for_pan-genotypic_hep_c_therapy_1191657

    Selina McKee PHARMA TIMES
    21 Apr 2017
    Share Share
    Japan Grants Priority Review to AbbVie's Investigational Regimen
    Japan Grants Priority Review to AbbVie's Investigational Regimen

    http://www.dddmag.com/news/2017/03/japan-grants-priority-review-abbvies-investigational-regimen-all-major-hcv-genotypes

    DDDMAG
    25 Mar 2017
    Share Share
    Aviragen takes a tumble as RSV drug fails mid-stage trial
    Aviragen takes a tumble as RSV drug fails mid-stage trial

    http://www.fiercebiotech.com/biotech/aviragen-takes-a-tumble-as-rsv-drug-fails-mid-stage-trial

    Phil Taylor  FIERCE BIOTECH
    02 Feb 2017
    Share Share
    SMC OKs four new therapies for NHS use in Scotland
    SMC OKs four new therapies for NHS use in Scotland

    http://www.pharmatimes.com/news/smc_oks_four_new_therapies_for_nhs_use_in_scotland_1184395

    Selina McKee PHARMATIMES
    18 Jan 2017
    Share Share
    Enanta reports positive results from phase 3 CERTAIN-1 study
    Enanta reports positive results from phase 3 CERTAIN-1 study

    http://www.pharmabiz.com/NewsDetails.aspx?aid=99744&sid=2

    PHARMABIZ
    11 Jan 2017
    Share Share
    Mylan Signs Sub-license Agreement with the Medicines Patent Pool
    Mylan Signs Sub-license Agreement with the Medicines Patent Pool

    http://www.prnewswire.com/news-releases/mylan-signs-sub-license-agreement-with-the-medicines-patent-pool-to-increase-access-to-hepatitis-c-treatment-in-developing-countries-300368162.html

    PR NEWSWIRE
    28 Nov 2016
    Share Share
    Recent Success in HCV Treatment Brings Relief to Patients
    Recent Success in HCV Treatment Brings Relief to Patients

    http://www.drug-dev.com/Main/Back-Issues/HCV-MARKET-Recent-Success-in-HCV-Treatment-Brings-1213.aspx

    DRUG DEVELOPMENT
    07 Nov 2016
    Share Share
    AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK
    AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK

    http://www.prnewswire.com/news-releases/abbvie-receives-us-fda-approval-of-supplemental-new-drug-application-for-viekira-pak-ombitasvir-paritaprevir-and-ritonavir-tablets-dasabuvir-tablets-without-ribavirin-in-genotype-1b-chronic-hepatitis-c-patients-with-compen-300256641.html

    PR NEWSWIRE
    26 Apr 2016
    Share Share
    Merck says its Zepatier showed better efficacy, safety compared with competition
    Merck says its Zepatier showed better efficacy, safety compared with competition

    http://www.pharmafile.com/news/503902/merck-says-its-zepatier-showed-better-efficacy-and-safety-compared-competition-phase-iii

    PHARMAFILE
    13 Apr 2016
    Share Share
    Australia bets $1B on pricey hepC drug in broad effort to eradicate the disease
    Australia bets $1B on pricey hepC drug in broad effort to eradicate the disease

    http://www.fiercepharma.com/story/australia-bets-1b-pricey-hep-c-drugs-broad-effort-eradicate-disease/2015-12-23

    Carly Helfand FIERCE PHARMA
    23 Dec 2015
    Share Share
    U.S. FDA approves Gilead's hepatitis C drug for expanded use
    U.S. FDA approves Gilead's hepatitis C drug for expanded use

    http://in.reuters.com/article/2015/11/12/us-gilead-sciences-fda-idINKCN0T12UA20151112?rpc=401

    REUTERS
    13 Nov 2015
    Share Share
    AbbVie nears launch of Viekira into crowded Japan HCV battle
    AbbVie nears launch of Viekira into crowded Japan HCV battle

    http://www.fiercepharmaasia.com/story/abbvie-nears-launch-viekira-crowded-japan-hcv-battle/2015-11-04

    EJ Lane FIERCE PHARMA ASIA
    05 Nov 2015
    Share Share
    Merck drug could offer Hep C cure to kidney disease patients
    Merck drug could offer Hep C cure to kidney disease patients

    http://www.pharmatimes.com/Article/15-10-06/Merck_drug_could_offer_Hep_C_cure_to_kidney_disease_patients.aspx

    Selina McKee PHARMATIMES
    06 Oct 2015
    Share Share
    AbbVie hepatitis C cocktail succeeds in late-stage study
    AbbVie hepatitis C cocktail succeeds in late-stage study

    http://www.reuters.com/article/2015/06/24/us-abbvie-study-idUSKBN0P413320150624

    Simon Jennings REUTERS
    25 Jun 2015
    Share Share
    Abbvie Reports Positive Phase 3 Study Results from all-Oral Treatment for Hepatitis C in Japan
    Abbvie Reports Positive Phase 3 Study Results from all-Oral Treatment for Hepatitis C in Japan

    http://www.pharmabiz.com/NewsDetails.aspx?aid=86515&sid=2

    Press Release PHARMABIZ
    03 Feb 2015
    Share Share
    Valeant Pharmaceuticals North America LLC , Ongoing Class II recall of Virazole (Ribavirin for Inhalation Solution, USP), Sterile Lyophilized For Administration by Aerosol Inhalation Only, Rx only, Contents: Four 6 g vials, 100 mL, Distributed by: Valeant Pharmaceuticals North America, Bridgewater, NJ 08807 USA, NDC 0187-0007-14. because of Non-Sterility: Valeant\'s laboratory observed a positive microbial contamination of Virazole lot 340353F, during testing at the 12 month stability pull.
    Valeant Pharmaceuticals North America LLC , Ongoing Class II recall of Virazole (Ribavirin for Inhalation Solution, USP), Sterile Lyophilized For Administration by Aerosol Inhalation Only, Rx only, Contents: Four 6 g vials, 100 mL, Distributed by: Valeant Pharmaceuticals North America, Bridgewater, NJ 08807 USA, NDC 0187-0007-14. because of Non-Sterility: Valeant's laboratory observed a positive microbial contamination of Virazole lot 340353F, during testing at the 12 month stability pull.

    http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0379-2015&w=01282015&lang=eng

    FDA
    28 Jan 2015
    Share Share
    NICE Backs New Hepatitis C Treatments
    NICE Backs New Hepatitis C Treatments

    http://www.pmlive.com/pharma_news/nice_backs_new_hepatitis_c_treatments_631606

    Thomas Meek PMLIVE
    16 Jan 2015
    Share Share
    Valeant Pharmaceuticals North America LLC Issues Voluntary Recall of Virazole® (ribavirin powder for solution) in the United States
    Valeant Pharmaceuticals North America LLC Issues Voluntary Recall of Virazole® (ribavirin powder for solution) in the United States

    http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-north-america-llc-issues-voluntary-recall-of-virazole-ribavirin-powder-for-solution-in-the-united-states-300014681.html

    Press Release PR NEWSWIRE
    02 Jan 2015
    Share Share
    CA Panel: Gilead's Harvoni Cost-Effective At $95K, But Only Affordable At Half the Price
    CA Panel: Gilead's Harvoni Cost-Effective At $95K, But Only Affordable At Half the Price

    http://www.fiercepharma.com/story/ca-panel-gileads-harvoni-cost-effective-95k-only-affordable-half-price/2014-12-15

    Tracy Staton FiercePharma
    15 Dec 2014
    Share Share
    Class Action Lawsuit Challenges the Exorbitant Pricing of Gilead\'s Hepatitis-C Drug Sovaldi
    Class Action Lawsuit Challenges the Exorbitant Pricing of Gilead's Hepatitis-C Drug Sovaldi

    http://www.Prnewswire.com/news-releases/class-action-lawsuit-challenges-the-exorbitant-pricing-of-gileads-hepatitis-c-drug-sovaldi-300007372.html

    Press Release Prnewswire
    09 Dec 2014
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search